NUI Galway’s Prof Matt Griffin presents NEPHSTROM to an array of international audiences

Professor Matthew Griffin of the National University of Ireland in Galway delivered lectures presenting NEPHSTROM research at a range of international venues in recent months. Below, find the titles of his talks, with the date, and audience composition.

  • “Diabetic Kidney Disease: The Promise of Regenerative Therapies”. REMEDI Seminar. Biomedical Sciences, NUI Galway

Date: May 23rd 2019.

Audience type: regenerative medicine researchers and postgraduate students

Number of attendees: 30

  • “Modulating the course of diabetic kidney disease: Are the pieces coming together?” Nephrology Grand Rounds, Mayo Clinic, Rochester, MN, USA.

Date: October 1st 2019.

Audience type: clinical nephrologists, nephrology trainees, laboratory scientists, translational researchers

Number of attendees: 60

  • “Modulating the Course of Diabetic Kidney Disease: The Role of Allogeneic Mesenchymal Stromal Cell Therapies” Seminar, Dept. of Immunology, Hebei Medical University, Shijiazhuang, China,

Date: October 31st 2019.

Audience type: laboratory researchers, postgraduate students, clinicians

Number of attendees: 50

  • “Understanding and targeting abnormal inflammation in chronic kidney disease”. HBB Seminar, NUI Galway,

Date: February 12th 2020.

Audience type: laboratory researchers, postgraduate students

Number of attendees: 30

  • “Stem cell research and chronic kidney disease in diabetes”. Advances in Diabetes Seminar. Hilton Hotel Kilmainham, Dublin

Date: March 6th 2020.

Audience type: consultant endocrinologists and endocrinology trainees

Number of attendees: 15

NEPHSTROM presented at RenalToolBox ITN Workshop, Galway

Coordinator Prof Tim O’Brien from NUI Galway presented aspects of NEPHSTROM at a recent Marie Curie Innovative Training Network workshop hosted in Galway. Coordinator O’Brien’s talk was entitled, “MSCs as a Therapy for Diabetic Complications.“ The online workshop was held on October 13th and 14th,

RenalToolBox, the ITN hosting the workshop, is taking a coordinated approach to develop novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies with a focus on kidney disease. See the workshop programme here.

NEPHSTROM Galway trial team adapts to new patient safety needs

Dr. Sarah Cormican, Dr. Veronica McInerney, Prof. Matthew Griffin and Mr. Nathan Devaney

The NEPHSTROM Galway trial team has developed a new trial visit workflow to meet the public health guidelines for COVID-19 protection for patients. They were able to successfully complete the end-of-study visit protocol for one of the NEPHSTROM patients and will complete further trial visits in a similar manner in July.

Prof Matthew Griffin, of NUI Galway and Galway University Hospitals, “To date, one end-of-study trial visit has been safely completed. This was only possible because of the expertise and ingenuity of Dr Veronica McInerney who developed the COVID-19 risk assessment and secured a safe location for us to run the protocol with minimal risk to all involved, and of Nathan Devaney and Sarah Cormican who spent the day along with Veronica working carefully with our patient and samples”.

 

PARTNER NEWS: LUMC constructs the largest stem cell facility for the Netherlands and beyond

NEPHSTROM partner Leiden University Medical Center (LUMC) will begin construction of the largest non-profit stem cell and gene therapy facility in the Netherlands in 2020. This will be one of the largest such facilities in Europe measuring at 4000 square metres. The Leiden facility is called NECSTGEN, the Netherlands Centre for the Clinical advancement of Stem Cell and Gene Therapies. Of particular interest to NEPHSTROM and the diabetes research community, NECSTGEN researchers are working on advancing regenerative medicine breakthroughs, such as insulin-producing cells grown on demand for diabetes patients.

The NECSTGEN is a public-private partnership. Researchers and start-ups will soon be welcomed in Leiden, NL in order to accelerate the application of regenerative medicine therapies. NECSTGEN is in part a collaboration with the Canadian Centre for Commercialisation of Regenerative Medicine (CCRM), who realised a similar facility in Toronto.

Currently, there are limited affordable, non-profit facilities where cell and cell product development for regenerative medical treatments are manufactured at scale.

Congratulations to LUMC and their partners for this great achievement and contribution to the regenerative medicine field!

Read the official press release here.

Regenerative Medicine Network publishes EU-MSC2 meeting report featuring NEPHSTROM

NEPHSTROM results were presented at EU-MSC2,  a bi-annual event, organized by partners Leiden University Medical Center in The Netherlands. The meeting assembles researchers, clinicians and cell product developers working within EU-sponsored research consortia, that focus on mesenchymal stromal cell (MSC) therapy for immune-related disorders and tissue regeneration. EU-MSC2, a much-anticipated event provides excellent opportunities for networking, exploring new funding opportunities and the dissemination of results contributing to MSC knowledge-sharing, research and development.

Dr Norberto Perico, Istituto di Ricerche Farmacologiche Mario Negri presented NEPHSTROM’s clinical trial in his September 5, 2019 talk entitled: MSC in diabetic nephropathy: initial clinical results from the NEPHSTROM trial. 

The comprehensive meeting report prepared by Katerina Apelt, Brigitte Wieles and Melissa van Pel of LUMC was published on April 29th, 2020, by the Regenerative Medicine Network.  Read it here.

NEPHSTROM Publication in PLoS One journal

Congratulations to NEPHSTROM partners at the Centre for Public Health, Queen’s University Belfast, the University Hospitals Birmingham, and the National University of Ireland Galway for their recent review: The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review published in PLoS ONE.

Sarah Elshahat, Paul Cockwell, Alexander P. Maxwell, Matthew Griffin, Timothy O’Brien, and Ciaran O’Neill are the authors of the study which appears in the March 24, 2020 edition of the open-access journal; PLoS ONE 15(3): e0230512. https://doi.org/10.1371/journal.pone.0230512

 

NEPHSTROM consortium meets January 30, 2020 in Dublin

The NEPHSTROM consortium reached a significant milestone when they held the tenth plenary project meeting in Dublin on January 30th, 2020. The meeting was hosted by Pintail Limited, and coincided with the successful treatment of the final patient to be included in the low dose cohort of the clinical trial and provided an opportunity for the consortium to review the progress made with the project as well as plan for the months ahead.

Three new NEPHSTROM-acknowledged papers

PI Prof Matthew Griffin of the National University of Ireland Galway has recently published three papers acknowledging NEPHSTROM work and funding:

  • Fazekas B and Griffin MD. “Mesenchymal stromal cell-based therapies for acute kidney injury: Progress in the last decade”, Kidney International, In Press, 2020 (Review). 28 January 2020. DOI: https://doi.org/10.1016/j.kint.2019.12.019 Pre-proof available here.
  • Swaminathan S and Griffin MD. Editorial: “Innovative biologics and drugs to target renal inflammation”, Frontiers Renal Pharmacol, In Press, 2020  DOI: 10.3389/fphar.2020.00038 Read the full article here.
  • Negi N and Griffin MD. “Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance”. Stem Cells, In Press, 29 January 2020 (Review). DOI: https://doi.org/10.1002/stem.3151 Download the pdf here.

Congratulations to Matt and his international colleagues!

Read the complete list of NEPHSTROM publications here: http://nephstrom.eu/nephstrom-publications/

Luke Barry joins the NEPHSTROM team at Queen’s University Belfast

Our PI Prof Ciaran O’Neill at Queen’s University Belfast reports that Luke Barry has joined the health economist researchers who are working on NEPHSTROM. Luke joined the Belfast team in November 2019. Welcome, Luke!
Queen’s University Belfast (QUB) is a member of the Russell Group of 24 leading UK research-intensive universities, providing world-class education underpinned by world-class research.

NEPHSTROM study published in Scientific Reports

Congratulations to the team of researchers Tomás Patrick Griffin, Md Nahidul Islam, Deirdre Wall, John Ferguson, Damian Gerard Griffin, Matthew Dallas Griffin and Paula M. O’Shea who published a NEPHSTROM-acknowledged study in Scientific Reports.  The open-access paper titled “Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential” can be found in the 5th of December 2019 edition with doi  https://doi.org/10.1038/s41598-019-54762-2. Alternatively, download the pdf here.

“Recent studies suggest a possible association between dephosphorylated-uncarboxylated MGP (dp-ucMGP) and glomerular filtration rate (GFR). This study aimed to establish normative data in an adult Caucasian population and to explore the potential utility of dp-ucMGP in patients with diabetes mellitus (DM) with and without diabetic kidney disease (DKD).”